Table 1.
Patients’ baseline characteristics (N = 20)
| Age | 66 ± 10.5 years |
| Female sex | 8 (40%) |
| Edoxaban dose |
60 mg daily: 15 (75%) 30 mg daily: 5 (25%) |
| Body weight | 80.5 ± 20.1 kg |
| Body Mass Index (BMI) | 27.0 ± 5.9 kg/m2 |
| Glomerular filtration rate (Cockcroft-Gault) | 83 ± 26 mL/min/1.73m2 |
| Risk factors | |
| Arterial hypertension | 16 (80%) |
| Hyperlipidemia | 7 (35%) |
| Diabetes mellitus | 1 (5%) |
| History of stroke | 20 (100%) |
| Congestive heart failure | 2 (10%) |
| Coronary heart disease | 7 (35%) |
| History of myocardial infarction | 5 (25%) |
| Smoking | 4 (20%) |
| Indication for edoxaban therapy | |
| Atrial fibrillation | 12 (60%) |
| Stroke associated with patent foramen ovale | 6 (30%) |
| Embolic stroke of undetermined source | 2 (10%) |
| Concomitant antiplatelet therapy | 4 (20%) |
Continuous variables are displayed as mean ± standard deviation. Nominal variables are displayed as absolute quantity (percentage)